Oral solid dosage is the most commonly used dosage to treat various diseases. These form of dosage is gaining popularity as it is cost-effective and easy to manufacture than other forms of dosage. Manufacturers are also producing oral solid dosage in different flavors to achieve patient compliance and acceptability. Companies are also focusing on design, shape and size of solid dosage to make it simple to swallow the tablets and capsules. Multiple oral solid dosage and user-friendly forms are also becoming popular. These dosage requires no measurements and are easy to swallow. The most popular form of dosage being manufactured are orally disintegrating granules, effervescent tablets, chewable tablets and hot and cold instant drinks.
According to the report by Future Market Insights (FMI), the global oral solid dosage pharmaceutical formulation market is anticipated to reach $926.3 billion by the end of 2027. It is also projected to register 6.5% CAGR during 2017-2027. New affluent customers in China, Korea and India are boosting the oral solid dosage pharmaceutical formulations in APEJ. North America is also expected to be the most lucrative market for oral solid dosage pharmaceutical formulation, reaching market attractiveness index of 2.7.
However, ongoing research on biologics molecule and the role they play in treating oncology conditions is restricting the growth of oral solid dosage pharmaceutical formulation. Moreover, government organizations are also investing in the research biologics along with biotech startups, this is also hampering the market growth. Major players are also betting on biologics due to the high returns.
Manufacturers to develop autonomous manufacturing environment to produce oral solid dosage
Manufacturers including GEA, G-Con and Pfizer recently entered into a partnership to develop a modern facility for oral solid dosage. The companies plan to create an autonomous and portable environment for the production of oral solid dosage. The development will use GCon’s modular system and ConsiGma 25 system by GCA. The currently developed prototype converts raw material into uncoated tablets in a few minutes, it is installed at Pfizer’s lab located in Groton.
The innovation is known as PCMM (Portable, Continuous, Miniature and Modular). The platform is designed and developed for manufacturing oral solid dosage. The manufacturer can use the equipment throughout the product lifecycle, helps to shorten development time and technology transfer.
Pfizer will use PCMM prototype to produce cGMP clinical supplies for releasing tablets for New Chemical Entities (NCE). Wet granulation and direct compression processes are used to produce uncoated tablets.
Emphasis on development of new oral solid dosage
Companies are emphasizing on developing user-friendly drugs, improving patient compliance, tackling polypharmacy problems. With help of emerging technologies, new devices are also being developed to produce oral solid dosage in faster and efficient manner. Companies are also using ingestible sensors to monitor drug misuse and compliance of drug administration. Technological advancements are also resulting in the development of personalized therapy and ensuring delivery of correct drug to improve therapy and produce better results.
The Quality by Design (QbD) and Process Analytical Technology (PAT) are also becoming mainstream and manufacturers are emphasizing on process controls and raw materials.